Category Archives: Psoriasis

Blasting for Skin Disorders
Skin disorders, like eczema, psoriasis, and others, are often worsened by eating the wrong foods. Longevity expert David Wolfe shows us some whole foods that not only help heal these disorders, but that taste great in a NutriBlast.From:thenutribulletViews:20 3ratingsTime:06:57More inPeople Blogs

More:
Blasting for Skin Disorders - Video

Psoriasis Treatment: When You Need Clear Skin Fast
Stop the itch immediately - really. Eliminate the symptoms - no joke. Naturally. One of the best psoriasis treatments you #39;ll find, and it #39;s all-natural. Hear testimonials on the website: DermaYantra.com. Derma Yantra is proud to be a leader in relief and treatment of psoriasis.From:DermaYantraViews:0 0ratingsTime:01:52More inHowto Style

Continued here:
Psoriasis Treatment: When You Need Clear Skin Fast - Video

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Idera Pharmaceuticals (IDRA) today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period. None of the 12 placebo-treated patients had improvement in this range; this difference was statistically significant (p<0.005). The Company believes the results of this trial provide clinical proof-of-concept for the mechanism of action of selective TLR inhibition in patients with psoriasis and potentially other autoimmune and inflammatory disorders.

The clinical activity of IMO-3100 demonstrated in patients with moderate-to-severe plaque psoriasis is encouraging, especially given the short duration of treatment in this study that was designed for initial explorations of safety and efficacy, commented Alexa Kimball, M.D., M.P.H., Vice Chair, Department of Dermatology at Massachusetts General Hospital, Boston, and an investigator in the trial.

The achievement of statistically significant PASI reductions with only four weeks of treatment in a placebo-controlled double-blind trial directly supports the rationale that the modulation of specific TLRs plays a key role in the treatment of psoriasis and, potentially, other autoimmune and inflammatory disorders, commented James Krueger, M.D., Ph.D., of The Rockefeller University, New York. We are excited to see these data, which demonstrate the translation of targeting a novel mechanism of action into clinical activity and support further studies of TLR antagonists for the treatment of psoriasis. Our laboratory is continuing to evaluate the immunological pathways by which TLR antagonists suppress the signaling cascades that underlie psoriasis and have the potential to open up a new approach to disease treatment.

About the IMO-3100 Phase 2 Trial in Psoriasis

The Phase 2 trial was a randomized, double-blind, placebo-controlled trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. In the trial, 44 patients were randomized to receive IMO-3100 monotherapy at 0.16 or 0.32 mg/kg or placebo by subcutaneous injection once weekly for four weeks with four weeks of follow-up. Assessments of safety were performed throughout the treatment and follow-up periods. Multiple parameters were monitored to assess the clinical activity of IMO-3100, including Psoriasis Area Severity Index (PASI), mean focal psoriasis severity and Physician Global Assessment (PGA) scores. In addition to the clinical assessments, biopsies of psoriasis plaques were evaluated for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action. Patients were enrolled at eleven sites in the United States.

Top-line clinical results from this trial include:

Skin biopsies were collected at baseline and after completion of treatment to investigate changes in epidermal thickness and immune cell infiltrates. Change in epidermal thickness was the primary endpoint for the trial. Placebo treated patients had a median change in epidermal thickness of +7.7% compared to a median change of -6.4% among IMO-3100 treated patients; this difference was not statistically significant. A known limitation of skin biopsies after four weeks of treatment is that psoriatic plaques do not resolve in a uniform fashion, and therefore, biopsies may not provide a representative sampling of lesions (ref: Ann Rheum Dis 2005;64:65-68).

The Company plans to present complete clinical data from this trial at an upcoming medical meeting.

We believe this trial in patients with moderate-to-severe plaque psoriasis provides clinical proof-of-concept for this first-in-class TLR antagonist, which represents a novel approach to the treatment of autoimmune diseases. We are very pleased to have observed clinical responses after only four weeks of treatment, stated Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera. The insights gained from this trial support expansion of our TLR antagonist program for the treatment of autoimmune diseases. In 2013, we plan to advance the clinical development of a selective TLR antagonist for the treatment of moderate-to-severe plaque psoriasis and also for the treatment of lupus.

View original post here:
Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to ...

6 x 120g Pots
Acheter sur le siite FR d #39;Amazon http://www.amazon.fr Descriptions du produit 6 x 120g Pots Our geranium and rose shea butter body butter is ideal as a deep hydrating body moisturiser, with a wonderfully feminine aphrodisiac scent and feel. No parabens, vegan, no added colour, 100% natural, with fair-trade shea butter. This SheaByNature intensive shea body butter is ideal for people with very dry skin, sensitive skin or ezcema, psoriasis, dermatitis prone skin. We have specially blended this body butter with some of Africa #39;s finest and most nutritious oils. This body butter contains 50 % unrefined shea shea butter so that you can benefit from both the healing and the moisturising qualities of this amazing oil. It has been fragranced with the seductive, floral, essential oils of Geranium and Rose. Unrefined shea Butter deeply moisturises, heals, protects and rejuvenates. Cocoa butter softens and enriches your skin. Coconut oil smoothes, moisturises and adds a healthy glow to your skin. Sunflower oil helps to improve the elasticity and suppleness of your skin. Our shea body butter will make an amazing difference to your skin. The romantic floral scent will make you fall in love.KEY INGREDIENTS: organic shea butter, cocoa butter, coconut oil, sunflower oil, vitamin E, essential oils of Rose and Geranium, cornstarchCase of 6 x 120g pots is ideal for gifts, party packs, starting a small business... Divulgation: ParanoShop participe au Programme Partenaires d #39;Amazon EU, un programme d ...From:Korey WallingViews:0 0ratingsTime:00:58More inHowto Style

See the original post:
6 x 120g Pots - Video

Psoriasis Free For Life Review - Natural Psoriasis Remedies
From:Sabine RadViews:0 0ratingsTime:03:39More inFilm Animation

Read more:
Psoriasis Free For Life Review - Natural Psoriasis Remedies - Video

Medicinal Orchid based Formulations for Psoriasis: Pankaj Oudhia #39;s Medicinal Plant Database
Quaternary Ingredients of Important Traditional Herbal Formulations from Pankaj Oudhia #39;s Medicinal Plant Database Medicinal Plants of India with reference to Healing Flora of Andhra Pradesh, Assam, Karnataka, Kerala, Chhattisgarh, Gujarat, Jharkhand, Madhya Pradesh, Maharashtra, Meghalaya, Sikkim, Arunachal Pradesh, Orissa, Rajasthan, Tamilnadu, Punjab, Haryana, West Bengal, Uttarakhand and Uttar Pradesh. - This video is a part of Compilation of Pankaj Oudhia #39;s Research Works at Indira Gandhi Agricultural University, Raipur, India (1990-2001), - This video is a part of Pankaj Oudhia #39;s report on Endangered Species of India. - This video is a part of Pankaj Oudhia #39;s report on Forgotten Herbal Formulations of the World with special reference to Asia. - This video is a part of Pankaj Oudhia #39;s report on North American and European Medicinal Species in Traditional Healing of Asia. - Pankaj Oudhia #39;s Traditional Knowledge Database on Medicinal Orchid based Herbal Formulations. For details please visit http://www.pankajoudhia.comFrom:Pankaj OudhiaViews:1 0ratingsTime:01:34More inScience Technology

More here:
Medicinal Orchid based Formulations for Psoriasis: Pankaj Oudhia's Medicinal Plant Database - Video

Home Remedies for Psoriasis on Hands - How to Cure Psoriasis Naturally
fastpsoriasiscure.org - Home Remedies for Psoriasis on Hands Psoriasis is one of the chronic skin afflictions that may result from infections, inappropriate medications, stress, genetic causes, skin injury and weather change. To get more information, please visit fastpsoriasiscure.orgFrom:Nengah HartawanViews:0 0ratingsTime:00:55More inHowto Style

See the article here:
Home Remedies for Psoriasis on Hands - How to Cure Psoriasis Naturally - Video

Pn. Hazlinda - Testimoni Psoriasis
From:Herba An-NabaatViews:0 0ratingsTime:02:19More inScience Technology

The rest is here:
Pn. Hazlinda - Testimoni Psoriasis - Video

ALLSCHWIL/BASEL, SWITZERLAND - 18 December 2012 - Actelion (ATLN.VX) announced today that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study conducted in 326 patients with moderate to severe chronic plaque psoriasis.

Results of the primary endpoint were highly statistically significant with both tested doses. With Ponesimod 20 mg, 46 % of patients improved by at least 75 % at week 16 (p<0.0001 versus placebo). With Ponesimod 40 mg, 48.1% of patients improved by at least 75 % at week 16 (p<0.0001 versus placebo). An improvement by at least 75 % was observed at week 16 in 13.4% of the placebo treated patients. Both doses were administered once daily.

At the end of induction, ponesimod patients improving at least 50% or more in their PASI score at week 16 were re-randomized to either continuation of the same dose of ponesimod, or to placebo.

After the initial 16 week induction phase of the study, further improvement was seen with ponesimod during the 12-week double-blind, placebo-controlled maintenance period. Among patients continuing on ponesimod 20 and 40mg, 71% and 77 % achieved PASI75 at the end of the study, respectively.

Efficacy was also demonstrated across other endpoints of the study, including Physician Global Assessment (PGA) at week 16.

Guy Braunstein, M.D. and Head of Clinical Development at Actelion commented: "This is the first time that this mechanism has demonstrated efficacy with psoriasis patients. Analysis during the maintenance period of the study showed patients continued to improve beyond the initial 16 week induction phase. Having conducted such a large Phase II study we have the information we need for the design of the pivotal Phase III program."

Safety and tolerability data from the study are consistent with the safety profile of ponesimod observed in previous studies conducted including the Phase II study with multiple sclerosis patients.[3] At initiation of ponesimod treatment, transient reductions in heart rate and less frequently, a transient effect on atrioventricular conduction were observed in the study as expected. The most frequent adverse events (AEs) reported for ponesimod was dose-dependent dyspnea and asymptomatic liver enzyme elevations. Overall, there were no indications of an increased infection rate with ponesimod in the study with the exposure to ponesimod up to 28 weeks. The safety data-base from all studies with ponesimod, now comprises more than 1,100 patients and healthy volunteers with some patients treated for up to 3.3 years.

Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "We are excited to now know that ponesimod, originating from Actelion`s discovery effort, has the potential to become an important treatment option in immune-mediated disorders in addition to multiple sclerosis. Actelion will rapidly move forward with the preparation of the pivotal program and discussions with health authorities for the psoriasis indication."

Once full data analysis has been concluded, Actelion will discuss the details of the upcoming Phase III program with health authorities. Actelion will present the results of this dose-finding study through scientific presentations and publications.

See the rest here:
Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis ...

How to Stop Mosquito Bites from Itching. Itchy skin remedies, Spider bite remedy.
Hello Face-book, You-tube and Twitter family! How the heck are you today? Today I #39;m going to take you through a little struggle I delt with when my home was invaded with spiders. These tips I give you will also work for eczema and psoriasis too! I #39;ve also labeled this the "um" video as I say the word um about 12 times:) Hey, do me a big ol favor, hit the "like" button for me and subscribe to my you-tube channel:)From:Andrea CoxViews:4 1ratingsTime:04:35More inEducation

See the original post here:
How to Stop Mosquito Bites from Itching. Itchy skin remedies, Spider bite remedy. - Video